Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: A cost-effectiveness analysis

Gut

Volumn 65, Issue 4, 2016, Pages 563-574

  Yeh, Jennifer M ^a   Hur, Chin ^b   Ward, Zachary ^a   Schrag, Deborah ^c   Goldie, Sue J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPSINOGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ENDOSCOPY; ENZYME BLOOD LEVEL; HELICOBACTER PYLORI; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SMOKING; STOMACH ADENOCARCINOMA; YOUNG ADULT; ADENOCARCINOMA; ADVERSE EFFECTS; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; GASTROSCOPY; HELICOBACTER INFECTIONS; INCIDENCE; MASS SCREENING; MIDDLE AGED; PROCEDURES; STOMACH NEOPLASMS; UNITED STATES;

ADENOCARCINOMA; ADULT; BIOMARKERS, TUMOR; COST-BENEFIT ANALYSIS; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PEPSINOGEN A; QUALITY-ADJUSTED LIFE YEARS; SMOKING; STOMACH NEOPLASMS; UNITED STATES;

EID: 84929593635     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308588     Document Type: Article

References (86)

1. Ferlay J, Soerjomataram I, Dikshit R., et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Howlader N, Noone A, Krapcho M., et al. SEER cancer statistics review, 1975-2011. Bethesda, MD, http://seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. National Cancer Institute, 2014.
3. Mizoue T, Yoshimura T, Tokui N., et al. Prospective study of screening for stomach cancer in Japan. Int J Cancer 2003;106:103-7.
4. Llorens P. Gastric cancer mass survey in Chile. Semin Surg Oncol 1991;7:339-43.
5. Pisani P, Oliver WE, Parkin D.M., et al. Case-control study of gastric cancer screening in Venezuela. Br J Cancer 1994;69:1102-5.
6. Correa P, Haenszel W, Cuello C., et al. A model for gastric cancer epidemiology. Lancet 1975;2:58-60.
7. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
8. de Martel C, Ferlay J, Franceschi S., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-15.
9. Chao A, Thun MJ, Henley S.J., et al. Cigarette smoking, use of other tobacco products and stomach cancer mortality in US adults: the Cancer Prevention Study II. Int J Cancer 2002;101:380-9.
10. Kneller RW, You WC, Chang Y.S., et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst 1992;84:1261-6.
11. Russo A, Maconi G, Spinelli P., et al. Effect of lifestyle, smoking, and diet on development of intestinal metaplasia in H. pylori-positive subjects. Am J Gastroenterol 2001;96:1402-8.
12. Kato I, Vivas J, Plummer M., et al. Environmental factors in Helicobacter pylori-related gastric precancerous lesions in Venezuela. Cancer Epidemiol Biomarkers Prev 2004;13:468-76.
13. Samloff IM, Varis K, Ihamaki T., et al. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology 1982;83:204-9.
14. Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 2010;105:493-8.
15. den Hoed CM, van Eijck BC, Capelle LG, et al. The prevalence of premalignant gastric lesions in asymptomatic patients: predicting the future incidence of gastric cancer. Eur J Cancer 2011;47:1211-18.
16. Miki K, Fujishiro M, Kodashima S., et al. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009;21:78-81.
17. Dinis-Ribeiro M, Yamaki G, Miki K., et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004;11:141-7.
18. Storskrubb T, Aro P, Ronkainen J., et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 2008;43:1448-55.
19. Yeh JM, Hur C, Kuntz K.M., et al. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 2010;116:2941-53.
20. Wong BC, Lam SK, Wong W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
21. Parsonnet J, Harris RA, Hack H.M., et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150-4.
22. Yeh JM, Hur C, Schrag D., et al. Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model. PLoS Med 2013;10:e1001451.
23. Fennerty MB, Emerson JC, Sampliner R.E., et al. Gastric intestinal metaplasia in ethnic groups in the southwestern United States. Cancer Epidemiol Biomarkers Prev 1992;1:293-6.
24. ∗Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2010 Sub (1973-2008) - Linked To County Attributes - Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission.
25. Gold MR, Siegel JE, Russel L.B., et al., eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
26. Eichler HG, Kong SX, Gerth W.C., et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28.
27. Neumann PJ, Sandberg EA, Bell C.M., et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000;19:92-109.
28. Guarner J, Bartlett J, Whistler T., et al. Can pre-neoplastic lesions be detected in gastric biopsies of children with Helicobacter pylori infection? J Pediatr Gastroenterol Nutr 2003;37:309-14.
29. Kruszon-Moran D, McQuillan GM. Seroprevalence of six infectious diseases among adults in the United States by race/ethnicity: data from the third national health and nutrition examination survey, 1988-94. Adv Data 2005:1-9.
30. Schoenborn CA, Adams PE. Health behaviors of adults: United States, 2005-2007. Vital Health Stat 2010;10:1-132.
31. Anderson CM, Burns DM, Dodd K.W., et al. Chapter 2: birth-cohort-specific estimates of smoking behaviors for the U.S. population. Risk Anal 2012;32(SUPPL. 1):S14-24.
32. Rosenberg MA, Feuer EJ, Yu B, et al. Chapter 3: cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Anal 2012;32(SUPPL. 1): S25-38.
33. Banatvala N, Mayo K, Megraud F., et al. The cohort effect and Helicobacter pylori. J Infect Dis 1993;168:219-21.
34. Kuipers EJ, Uyterlinde AM, Pena A.S., et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525-8.
35. Xia HH, Talley NJ. Natural acquisition and spontaneous elimination of Helicobacter pylori infection: clinical implications. Am J Gastroenterol 1997;92:1780-7.
36. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005;100:2083-99.
37. U.S. Department of Health and Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. DHHS Publication No. (CDC) 90-8416. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health, 1990.
38. The Berkeley Mortality Database. http://www.demog.berkeley.edu/~bmd/ (accessed 24 Sep 2013).
39. Bell FC, Miller ML. Life tables for the United States Social Security area 1900-2100. SSA Pub No 11-11536. Baltimore, MD: Social Security Administration, Office of the Chief Actuary, 2005.
40. Thun MJ, Myers DG, Day-Lally C, et al. Chapter 5: age and the exposure-response relationships between cigarette smoking and premature death in cancer prevention study II. In: Burns DM, Garfinkel L, Samet JM. eds. Changes in cigarette related disease risks and their implication for prevention and control. Smoking and tobacco control monograph No 8 NIH publication No 97-4213. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 1997.
41. Ladeiras-Lopes R, Pereira AK, Nogueira A, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 2008;19:689-701.
42. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health 1998;88:15-19.
43. de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945-52.
44. de Vries AC, Haringsma J, de Vries RA, et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter 2010;15:259-64.
45. Watanabe Y, Ozasa K, Higashi A., et al. Helicobacter pylori infection and atrophic gastritis. A case-control study in a rural town of Japan. J Clin Gastroenterol 1997;25:391-4.
46. Burucoa C, Delchier JC, Courillon-Mallet A, et al. Comparative evaluation of 29 commercial Helicobacter pylori serological kits. Helicobacter 2013;18:169-79.
47. Loy CT, Irwig LM, Katelaris P.H., et al. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996;91:1138-44.
48. Guarner J, Herrera-Goepfert R, Mohar A., et al. Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. Hum Pathol 2003;34:28-31.
49. Hosokawa O, Miyanaga T, Kaizaki Y., et al. Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. Scand J Gastroenterol 2008;43:1112-15.
50. Schauer PR, Schwesinger WH, Page C.P., et al. Complications of surgical endoscopy. A decade of experience from a surgical residency training program. Surg Endosc 1997;11:8-11.
51. Kim SY, Sung JK, Moon H.S., et al. Is endoscopic mucosal resection a sufficient treatment for low-grade gastric epithelial dysplasia? Gut Liver 2012;6:446-51.
52. Ahn JY, Jung HY, Choi K.D., et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc 2011;74:485-93.
53. Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev 2009;(4):CD004276.
54. Kojima T, Parra-Blanco A, Takahashi H., et al. Outcome of endoscopic mucosal resection for early gastric cancer: review of the Japanese literature. Gastrointest Endosc 1998;48:550-4; discussion 554-5
55. Glance LG, Lustik SJ, Hannan E.L., et al. The surgical mortality probability model: derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg 2012;255:696-702.
56. McNicholl AG, Linares PM, Nyssen O.P., et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012;36:414-25.
57. Choi KS, Jung HY, Choi K.D., et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. Gastrointest Endosc 2011;73:942-8.
58. Hanmer J, Lawrence WF, Anderson J.P., et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006;26:391-400.
59. Gold MR, Franks P, McCoy K.I., et al. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36:778-92.
60. Centers for Medicare and Medicaid Services. Research, Statistics, Data & Systems. 2012. http://www.cms.gov/Research-Statistics-Data-and-Systems/Research-Statistics-Data-and-Systems.html (accessed 1 Feb 2013).
61. RED BOOK Online™. Truven health analytics. Micromedex Solutions, 2013. http://micromedex.com/redbook (accessed 28 Feb 2013).
62. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630-41.
63. Bureau of Labor Statistics, U.S. Department of Labor. Occupational employment and wages. DC: U.S. Government Printing Office. http://www.bls.gov/oes/ (accessed 15 Feb 2013).
64. Yabroff KR, Davis WW, Lamont E.B., et al. Patient time costs associated with cancer care. J Natl Cancer Inst 2007;99:14-23.
65. Birkmeyer JD, Siewers AE, Finlayson E.V., et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-37.
66. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013;368:351-64.
67. Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006;4:709-16.
68. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia. J Gastroenterol Hepatol 2007;22:1594-604.
69. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F., et al. Serum pepsinogen test for early detection of gastric cancer in a European country. Eur J Gastroenterol Hepatol 2012;24:37-41.
70. Yanaoka K, Oka M, Mukoubayashi C., et al. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008;17:838-45.
71. Oishi Y, Kiyohara Y, Kubo M., et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006;163:629-37.
72. Miki K, Morita M, Sasajima M., et al. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003;98:735-9.
73. Mizuno S, Kobayashi M, Tomita S., et al. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer 2009;12:158-63.
74. Shikata K, Ninomiya T, Yonemoto K., et al. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scand J Gastroenterol 2012;47:669-75.
75. Correa P. Serum pepsinogens in gastric cancer screening. Dig Dis Sci 2010;55:2123-5.
76. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007;8:8-14.
77. Aberle DR, Adams AM, Berg C.D., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365: 395-409.
78. Church TR, Black WC, Aberle D.R., et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368:1980-91.
79. Humphrey LL, Deffebach M, Pappas M., et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med 2013;159:411-20.
80. Schoen RE, Pinsky PF, Weissfeld J.L., et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366: 2345-57.
81. Miki K, Fujishiro M. Cautious comparison between East and West is necessary in terms of the serum pepsinogen test. Dig Endosc 2009;21:134-5.
82. Fendrick AM, Chernew ME, Hirth R.A., et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999;159:142-8.
83. Li WQ, Ma JL, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst 2014;106:dju116.
84. Freedberg DE, Abrams JA, Wang TC. Prevention of gastric cancer with antibiotics: can it be done without eradicating Helicobacter pylori? J Natl Cancer Inst 2014;106:dju148.
85. Agreus L, Storskrubb T, Aro P., et al. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol 2009;44:564-70.
86. Lunet N, Barros H. Helicobacter pylori infection and gastric cancer: facing the enigmas. Int J Cancer 2003;106:953-60.